Veracyte Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Veracyte stock.
View analyst ratings for Veracyte or view top-rated stocks.

Wall Street analysts have given Veracyte a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Veracyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Veracyte is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Veracyte.

Veracyte, Inc. (NASDAQ:VCYT) announced its quarterly earnings data on Monday, May, 10th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.01. The biotechnology company had revenue of $36.70 million for the quarter, compared to analysts' expectations of $34.52 million. Veracyte had a negative trailing twelve-month return on equity of 5.91% and a negative net margin of 52.87%.
View Veracyte's earnings history.

Veracyte's stock was trading at $23.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VCYT stock has increased by 53.5% and is now trading at $36.14.
View which stocks have been most impacted by COVID-19.

Veracyte issued an update on its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $190 million-200 million, compared to the consensus revenue estimate of $194.19 million.

9 brokerages have issued twelve-month price objectives for Veracyte's shares. Their forecasts range from $45.00 to $65.00. On average, they anticipate Veracyte's stock price to reach $54.75 in the next year. This suggests a possible upside of 51.5% from the stock's current price.
View analysts' price targets for Veracyte or view top-rated stocks among Wall Street analysts.

Some companies that are related to Veracyte include Natera (NTRA), Invitae (NVTA), CareDx (CDNA), Burning Rock Biotech (BNR), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Genetron (GTH), RadNet (RDNT), DermTech (DMTK), Renalytix AI (RNLX), Personalis (PSNL), Celcuity (CELC), Exagen (XGN), Centogene (CNTG) and Enzo Biochem (ENZ).
View all of VCYT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.33%), BlackRock Inc. (9.14%), Artisan Partners Limited Partnership (6.98%), William Blair Investment Management LLC (6.83%), Nikko Asset Management Americas Inc. (4.89%) and Sumitomo Mitsui Trust Holdings Inc. (4.85%). Company insiders that own Veracyte stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Mark Ho and Robert S Epstein.
View institutional ownership trends for Veracyte.

VCYT stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, William Blair Investment Management LLC, Gilder Gagnon Howe & Co. LLC, Waddell & Reed Financial Inc., Capital Impact Advisors LLC, Lord Abbett & CO. LLC, Cubist Systematic Strategies LLC, and Nuveen Asset Management LLC. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Mark Ho, and Robert S Epstein.
View insider buying and selling activity for Veracyte or view top insider-selling stocks.

VCYT stock was purchased by a variety of institutional investors in the last quarter, including Matrix Capital Management Company LP, Artisan Partners Limited Partnership, BlackRock Inc., Oak Ridge Investments LLC, Jennison Associates LLC, Champlain Investment Partners LLC, Goldman Sachs Group Inc., and Canada Pension Plan Investment Board.
View insider buying and selling activity for Veracyte or or view top insider-buying stocks.

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCYT stock can currently be purchased for approximately $36.14.

Veracyte has a market capitalization of $2.43 billion and generates $117.48 million in revenue each year. The biotechnology company earns $-34,910,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis.

Veracyte employs 320 workers across the globe.

The official website for Veracyte is www.veracyte.com.

Veracyte is headquartered at 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]